Phase III ECZTEND long term study of Adbry shows consistency with other studies in atopic dermatitis – LEO Pharma
LEO Pharma announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD). The… read more.
